{"nctId":"NCT01723904","briefTitle":"A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease","startDateStruct":{"date":"2012-10"},"conditions":["Advanced Parkinson's Disease"],"count":90,"armGroups":[{"label":"Rotigotine","type":"EXPERIMENTAL","interventionNames":["Drug: Rotigotine"]}],"interventions":[{"name":"Rotigotine","otherNames":["Neupro"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is male or female, aged ≥ 30 and \\< 80 years at informed consent\n* Subject has idiopathic Parkinson's Disease, of more than 3 years duration, as defined by the cardinal sign, bradykinesia, and the presence of at least 1 of the following: resting tremor, rigidity, impairment of postural reflexes, and without any known or suspected cause of Parkinsonism\n* Subject has motor fluctuations such as wearing, dyskinesia\n* Subject has experienced nocturias for at least 3 nights within 7 days prior to Baseline\n* Subject is taking levodopa (L-DOPA, immediate and/or controlled release) in combination with benserazide or carbidopa and has been on a stable dose of L-DOPA for at least 28 days prior to Baseline (Visit 2)\n* Subject is taking a non-ergot dopamine agonist (pramipexole ≤ 1.5 mg/day or ropinirole ≤ 6.0 mg/day) and has been on a stable dose of non-ergot dopamine agonist for at least 28 days prior to Baseline (Visit 2)\n\nExclusion Criteria:\n\n* Subject is receiving therapy with tolcapone or budipine\n* Subject is receiving therapy with one of the following drugs either concurrently or within 28 days prior to Baseline (Visit 2): alpha-methyl dopa, metoclopramide, reserpine, neuroleptics (except specific atypical neuroleptics: olanzapine, ziprasidone, aripiprazole, clozapine, quetiapine), monoamine oxidase A (MAO-A) inhibitors, methylphenidate, or amphetamine\n* Subject has a history of symptomatic (not asymptomatic) orthostatic hypotension within the 6 months prior to Baseline (Visit 2)\n* Subject has a known hypersensitivity to any components of the study medication, such as a history of significant skin hypersensitivity to adhesives, known hypersensitivity to other transdermal medications, or has unresolved contact dermatitis\n* Subject is pregnant or nursing, or is of child-bearing potential (ie, is (i) not surgically sterile, or, (ii) not using adequate birth control methods \\[including at least one barrier method\\] or, (iii) not sexually abstinent, or (iv) not at least 2 years post menopausal)\n* Subject had a previous diagnosis of narcolepsy, sleep apnea syndrome, restless legs syndrome, or periodic limb movement disorder","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period","description":"The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows: 0 = Side effects not assessable\n\n1. = No side effects\n2. = Side effects do not significantly interfere with subject's functioning\n3. = Side effects significantly interfere with the subject's functioning\n4. = Side effects outweigh therapeutic efficacy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (\"on\" State) Total Score","description":"The Unified Parkinson´s Disease Rating Scale Part III is an accepted and validated scale for the assessment of motor function in Parkinson´s disease. Each of the 27 sub-items in the UPDRS III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total scores therefore ranges from 0 to 108.\n\nA negative value in Change from Baseline to Week 8 indicates an improvement in motor functions from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.3","spread":"8.3"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Average of \"on\" and \"Off\" State) Total Score","description":"UPDRS Part II measures 'Activities in Daily Living'. The total score ranges from 0 (Best score possible) to 52 (Worst score possible).\n\nUPDRS Part II total score (average of \"on\" and \"off\" state) is the average of UPDRS Part II total score (\"on\" state) and Part II total score (\"off\" state).\n\nA negative value in Change from Baseline to Week 8 indicates an improvement in activities in daily living from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"3.8"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to the End of the Treatment Period in Absolute Time Spent \"Off\"","description":"Absolute time spent \"off\" is measured in hours per day. A negative value in Change from Baseline to Week 8 indicates that the time spent \"off\" decreased from Baseline and therefore indicates an improvement from Baseline.\n\nOnly subjects with time spent \"off\" at Baseline (subset of the Full Analysis Set (FAS)) are included in the analysis of this outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the End of the Treatment Period in Time Spent \"on\" Without Troublesome Dyskinesia","description":"Absolute time spent \"on\" without troublesome dyskinesia is measured in hours per day. A positive value in Change from Baseline to Week 8 indicates that the time spent \"on\" without troublesome dyskinesia increased from Baseline and therefore indicates an improvement from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"3.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the End of Treatment Period in Parkinson's Disease Sleep Scale 2 (PDSS-2) Total Score","description":"The Parkinson´s Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep disturbance and nocturnal disability in Parkinson´s disease. The item- scores can range between 0= never and 4= very often. The PDSS score is a sum score of all 15 questions.\n\nA negative value in Change from Baseline to Week 8 indicates an improvement from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"7.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to the End of Treatment Period in the Pittsburgh Sleep Quality Index (PSQI) Global Score","description":"The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire with 18 questions to assess sleep quality. The 18 questions are distributed to 7 elements with each element ranging from 0-3. The global score is the sum score of all 7 elements and ranges from 0-21 with higher values indicating worse sleep quality.\n\nA negative value in Change from Baseline to Week 8 indicates an improvement in sleep quality from Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"3.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":90},"commonTop":["Application site pruritus","Dizziness","Orthostatic hypotension","Nausea","Dyskinesia"]}}}